Innerva Pharmaceuticals Raises €2.3M to Develop a New First-in-Class Treatment for Ocular Pain
Innerva Pharmaceuticals (Innerva) has closed a €2.3 million funding round led by venture capital manager Inveready through the Inveready Biotech III Fund.
Innerva Pharmaceuticals (Innerva), a company developing a new drug for treating ocular pain associated with dry eye and other surface diseases, has closed a €2.3 million funding round led by venture capital manager Inveready through the Inveready Biotech III Fund. The financing round also saw participation from BStartup of Banco Sabadell and various business angels.
21/10/2022
Innerva Pharmaceuticals Raises €2.3M to Develop a New First-in-Class Treatment for Ocular Pain
Innerva Pharmaceuticals (Innerva) has closed a €2.3 million funding round led by venture capital manager Inveready through the Inveready Biotech III Fund.